The global biochips market size was valued at USD 7.92 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 13.35% from 2022 to 2030. Biochip is becoming a hotspot segment for emerging players to mature. This is attributed to the rising drug development, increasing adoption of personalized medicines, as well as next-generation sequencing (NGS). Innovation in the Lab-on-a-chip offerings along with the biomedical advancement for microfluidic-based devices is expected to contribute to the industry growth. LOC devices are expected to deliver rapid results at the initial diagnosis of infectious diseases. The technology is widely utilized in epidemiological studies.
The health crisis of the COVID-19 pandemic impacted the supply chain of the biochip and resulted in a mismatch of supply and demand levels. The product demand increased with support from academic institutions and biopharma companies. For instance, in January 2022, a group of researchers from The Czech Academy of Sciences (the CAS) developed a system with a biochip to detect the COVID-19 virus. According to the researchers, a biochip is as rapid as an antigen test and as accurate as PCR testing. The combination of biochip technology with various applications is projected to boost industry growth.
For instance, in March 2022, a U.S.-based startup, Nutcracker raised funds worth USD 167 million via series C to enhance the RNA manufacturing platform based on a biochip. The biochip-based platform is expected to support the advancement of RNA-based therapeutics. The biochip as well as nanoparticle delivery technology assist in establishing comprehensive isolated and automated manufacturing. In addition, the acceleration in the use of biochip applications including drug development, obligated several R&D institutions and R&D teams to design a cost-effective and efficient process. In 2021, more than 700 drugs were in-progress for targeting approximately 8,000 rare diseases.
Biochips are utilized for testing drugs before their clinical trials. In May 2022, Vienne University of Technology, TU Wien, innovated a biochip-based technology to manufacture tissue beads in precise sizes and commercialize them along with drugs through a thin channel. Moreover, the patent application for this technology has been submitted. However, the manufacturing cost of biochips can restrain the growth of the industry. The majority of microfluidic devices are made of ultraviolet lithography, an extremely complex and costly technique that requires trained professionals with specialized instruments.
The high cost of manufacturing creates high barriers for new players to enter the market and produce a wide range of alternatives for the end-users. The low level of awareness in the developing and under-developed regions about the utility of biochips is also a concerning factor for the industry. Over a few years, the quantity of biochip-based research by research and academic institutes in developing countries has decreased. Limited knowledge among emerging companies in the drug development and personalized medicine sector is projected to limit industry growth.
The DNA chips segment dominated the global industry in 2021 and accounted for the highest share of more than 39.50% of the overall revenue. They are majorly used in academic research and clinical diagnostic tests for numerous diseases. For instance, in November 2021, Roswell Biotechnologies, a San Diego biotech company, is developing a molecular microchip that can take the molecule of an individual and assess it. The technology is anticipated to change the techniques of disease detection, development of drugs, and monitoring of health. The company aims to use the chip to enhance DNA sequencing. In DNA chips, the cancer diagnosis and treatment segment held a significant share in 2021. Biochips are projected to replace traditional medical diagnostic tasks, including cancer detection.
They are inexpensive, rapid, and widely available, hence enabling advanced detection of cancer to occur in numerous localities. It also eases the adoption process of telemedicine in the market. Similarly, Singapore's Institute of Bioengineering and Nanotechnology have designed a biochip that can detect drug-resistant cancer cells. The Lab-On-chips (LOC), on the other hand, is expected to register the fastest CAGR during the projected period. Since the usage of LOC in the area of medicine is increasing, it is expected to assist in early diagnostics, drug patents, and personalized medicine. Hence, factors, such as low costs and low sample volumes, are expected to extend the use of LOC technology in point-of-care diagnostics in emerging countries.
The biotechnology and pharmaceutical companies segment accounted for the highest revenue share of more than 55.90% in 2021. The companies are indulging in heavy R&D programs to integrate biochip technology in various health applications. Considering the competitiveness in the pharmaceutical market, the companies cannot afford to invest heavily in developing drugs that have the probability of failing FDA approval. However, biochips are anticipated to be a new pathway to the discovery and development of drugs. Biochips are employed to develop biomarkers in the process of drug discovery, primarily for Single Nucleotide Polymorphism (SNP) analysis and gene expression profiling.
On the other hand, the academic & research institutes' end-use segment is projected to register the highest growth rate from 2022 to 2030. The institutions are conducting R&D on the technology and exploring various applications for biochips. For instance, in January 2022, a team of professionals from the Universidad Carlos III de Madrid (UC3M), the Universidad Politécnica de Madrid (UPM), along with other institutions, designed an advanced biochip that eases the manufacturing process of in vitro skin in the labs. The device is expected to be used in the testing of medicine and cosmetics.
North America dominate the global industry in 2021 and accounted for the largest share of more than 48.40% of the overall revenue. The region is expected to maintain the industry position during the forecast period owing to the rising initiatives of the government for enhancing R&D through tax credits. The high existence of biotechnology companies along with academic and research institutions in the region is anticipated to boost further technology advancements in the applications of biochips. In the U.S., R&D tax credit is a budgetary benefit provided by the central government by offering companies dollar-for-dollar cash saving for carrying-out research activities to innovate, develop, or enhance products, processes, formulas, or software.
It is observed that a company can be offered a tax credit of around 12-16% for every dollar. The Asia Pacific region is estimated to register the fastest growth rate during the projected period. The fast-paced growth of this region will be mainly driven by China and India. The key determinants of industry growth in the region are enhancing the approachability to the technologies, a large patient pool, and improvement in healthcare infrastructure. The increasing adoption of biochip technology outsourcing to emerging markets by mature players to lower overall production costs is also a significant factor driving the region’s growth.
The industry is an attractive market for investors, hence the ease of fundraising by startups has increased. The existing players are executing numerous strategies, such as developing the product for various applications, indulging in partnerships and strategic collaborations via mergers and acquisitions, and regional expansions, to expand their industry presence. For instance, in August 2022, Abbott announced the outcome of a research that used Abbott's i-STAT TBI Plasma test, a portable analyzer, to detect two biomarkers associated with brain injury in blood. The study concluded that the product can assist in projecting the recovery of a patient from a traumatic brain injury and offer important insights. Some of the key players in the global biochips market include:
Abbott Laboratories
Agilent Technologies, Inc.
PerkinElmer, Inc.
Fluidigm Corporation
Illumina, Inc.
GE Healthcare
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific, Inc.
LI-COR, Inc.
Molecular Devices, LLC.
Report Attribute |
Details |
Market size value in 2022 |
USD 9.51 billion |
Revenue forecast in 2030 |
USD 25.92 billion |
Growth rate |
CAGR of 13.35% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; South Korea; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Abbott Laboratories; Agilent Technologies, Inc.; PerkinElmer, Inc.; Fluidigm Corp.; Illumina, Inc.; GE Healthcare; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; LI-COR, Inc.; Molecular Devices, LLC |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global biochips market report on the basis of type, end-use, and region.
Type Outlook (Revenue, USD Million, 2018 - 2030)
DNA Chips
Cancer Diagnosis And Treatment
Gene Expression
SNP Genotyping
Genomics
Drug Discovery
Agricultural Biotechnology
Others
Protein Chips
Proteomics
Expression profiling
Diagnostics
HTS
Drug discovery
Others
Lab-on-chip
Genomics
IVD & POC
Proteomics
Drug Discovery
Others
Tissue Arrays
Cell Arrays
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Biotechnology And Pharmaceutical Companies
Hospitals And Diagnostics Centers
Academic & Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global biochip market size was estimated at USD 7.92 billion in 2021 and is expected to reach USD 9.51 billion in 2022
b. The global biochip market is expected to grow at a compound annual growth rate of 13.35% from 2022 to 2030 to reach USD 25.92 billion by 2030.
b. DNA chips dominated the biochip market with a share of 35.32% in 2021. DNA chips are projected to replace traditional medical diagnostics tasks, including cancer detection. Since they are inexpensive, rapid, and widely available, hence enable advanced detection of cancer to occur in numerous locality
b. Some of the key market players include biochips, Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer, Inc., Fluidigm Corporation, and Illumina, Inc.
b. Key factors driving the market growth include an increase in the adoption of next-generation sequencing, growing R&D in proteomics and genomics, the presence of an extensive drug-development pipeline, increasing adoption of personalized medicine, and rapid technological advances in biochip technology.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.